T HE heart rate (HR) response to the systemic administration of calcium channel blockers seems to vary depending on the specific calcium channel blocker selected. Some of these differences may be due to a direct effect of the calcium antagonist on the baroreceptor reflex.' However, the sites of action for these drugs in the baroreceptor reflex are not well understood.
T HE heart rate (HR) response to the systemic administration of calcium channel blockers seems to vary depending on the specific calcium channel blocker selected. Some of these differences may be due to a direct effect of the calcium antagonist on the baroreceptor reflex.' However, the sites of action for these drugs in the baroreceptor reflex are not well understood.
In most of the earlier studies, baroreceptor reflex function was assessed upon intravenous infusion of the calcium channel antagonist. 2 -6 Thus, the site of action of the drug could have been anywhere in the baroreceptor reflex pathway, since calcium channel blockers may have modulated the afferent or the efferent part of the pathway (or both) by relaxing the vascular smooth muscle or they may have modulated the central nervous component of the pathway after crossing the blood-brain barrier. The results of the few studies that have attempted to assess the direct effects of calcium channel blockers on the baroreceptors, using carotid sinus or aortic arch preparations, 7 -8 are somewhat conflicting. Blockade of voltage-dependent calcium channels at therapeutic concentrations did not seem to alter baroreceptor transduction in the work of Kunze et al., 8 while Heesch et al. 7 reported that nifedipine enhanced multiunit baroreceptor activity. Recently, Higuchi et al. 9 suggested that a central nervous component of the baroreceptor reflex pathway was sensitive to the dihydropyridine-derived calcium channel antagonists. However, no study of the central effects of dihydropyridines on baroreceptor reflex function has been done.
There are several arguments for the hypothesis that baroreceptor reflex function is modulated centrally by dihydropyridines. Dihydropyridine receptor sites have been found in the brain. 10 - 12 Recent findings support a physiological role for these sites. The dihydropyridine derivatives, either calcium channel agonists or antagonists, have been shown to modulate the stimulated release from brain tissue of neurotransmitters involved in the central control of blood pressure and HR: acetylcholine, 13 -14 dopamine, 13 -15 serotonin, 16 and norepinephrine. 17 Moreover, the effects of dihydropyridines on the release of transmitters were correlated with changes in the net voltage-dependent entry of calcium into synaptosomes. 13 - 17 These data suggest that calcium channel modulators may influence the autonomic nervous system at the central level.
Higuchi et al. 9 - 18 reported an excitatory effect on the nucleus tractus solitarii when nifedipine was administered into the cisterna magna or when the local availability of calcium was reduced, resulting in hypotension and bradycardia in conscious rats. We have previously shown 19 that the dihydropyridine derivatives BAY k 8644 (methy 1-1,4-dihydro-2,6 -dimethyl-3 -nitro-4 -[2 -trifluoromethylphenyl]-pyridine-5-carboxylate), a calcium channel agonist, 20 and nifedipine, a calcium channel antagonist, increased and decreased mean arterial pressure (MAP) respectively, when intracerebroventricularly (i.c.v.) injected in anesthetized spontaneously hypertensive rats (SHR) by a mechanism of central origin. No tachycardia accompanied the hypotensive response to i.c.v. administered nifedipine, in contrast to that reported after oral or intravenous administration. 21 These findings suggest that central dihydropyridine receptor sites may play a role in the control of blood pressure and baroreceptor reflex function.
In light of this evidence, the present study was designed to examine the effects of the dihydropyridine derivatives PN 200-110 (isopropyl 4-[2,l,3-benzoxadiazol-4 -yl]-1,4-dihydro-5 -methoxycarbony-2,6-dimethyl-3-pyridine carboxylate), a calcium channel antagonist, 22 or BAY k 8644, a calcium channel agonist, 20 on the central nervous component of the baroreceptor reflex control of HR during activation of baroreceptors by phenylephrine. To rule out an effect on peripheral vessels or on the sinoauricular node (or on both) and to allow conclusions about a central effect, dihydropyridines were administered i.c.v. at doses that did not change MAP. These experiments were performed in anesthetized SHR, in which significant changes in blood pressure were observed in previous experiments after i.c.v. or intracisternal administration of nifedipine or BAY k 8644 as compared with responses in normotensive rats. 19 Since the pressor effect of i.c.v. administered BAY k 8644 was reported to involve a central increase in muscarinic cholinergic activity in anesthetized SHR, 14 we tested the hypothesis that the BAY k 8644-induced change in baroreceptor reflex sensitivity (BRS) was mediated by a change in central cholinergic activity, using central administration of the muscarinic receptor antagonist atropine methylnitrate (AMN).
Materials and Methods
Male, 14-week-old normotensive Wistar rats and SHR (Okamoto strain, Iflfa-Credo, Fresnes, France) weighing 300 to 350 g were anesthetized with pentobarbital (50 mg/kg i.p.). The trachea was cannulated, and the animals were artificially ventilated by means of a Palmer "Ideal" 10 pump (London, England). Instantaneous pressure and MAP were recorded continuously from a femoral artery by means of a Statham P23Db pressure transducer (Oxnard, CA, USA) on two channels of a GouldBrush 3302 recorder (Cleveland, OH, USA). HR was continuously recorded from the electrocardiographic signal. A femoral vein was cannulated with a polyethylene catheter for the administration of phenylephrine, propranolol, or AMN.
Central administrations of drugs were performed as previously described. 19 Briefly, i.c.v. injections were performed through a cannula inserted into one of the lateral cerebral ventricles through a trephine hole drilled 2 mm lateral and 2 mm posterior to the bregma, at a depth of 3.5 to 4 mm from the top of the skull. All drugs were administered in a 1.5-fil volume for 1 minute. Arterial pressure and HR were recorded for 65 minutes following central administration. In preliminary experiments, increasing doses of PN 200-110 (0.2, 0.6, 2, 10 /ig/kg) and BAY k 8644 (1, 3, 10, 30 ^g/kg) were administered i.c.v. to SHR to determine the threshold dose for a significant change in MAP. Only one dose of PN 200-110 or BAY k 8644 was administered in each rat.
BRS was determined using the method of Smyth et al. 23 with minor modifications. Intravenous injections of phenylephrine (2 jig) were used to induce systolic blood pressure (SBP) changes larger than 20 mm Hg. For each injection, the linear relationship between the drug-induced changes in SBP and heart period (msec) was computed. Since a latency exists in the heart period response that is close to 1 second in humans as well as in rats, 24 -26 we calculated in preliminary experiments the relationship between SBP and heart period with different shifts ( + 4 to +10 beats), as indicated by Struyker Boudier et al. 24 The highest correlation coefficients and slopes were obtained with a shift of +9 beats, which was used for all calculations. Under these conditions, the slope of the relationship was used as an index of BRS and expressed in milliseconds per millimeter of mercury ( Figure 1 ). We discarded the few animals in which the correlation coefficient of the relationship between SBP and heart period, 
Results
BRS was significantly lower in SHR than in normotensive Wistar rats at the 40th minute following the onset of anesthesia (0.09 ± 0.03 vs 0.33 ± 0.08 msec/mm Hg; p < 0.02). In both strains, BRS increased with time (see Figure 2) . In SHR as well as in normotensive rats, BRS was significantly higher at the 65th minute (p < 0.05) than at the 40th minute (SHR, 0.39 ± 0.08 vs 0.09 ± 0.03 msec/mm Hg;n = 6, p< 0.01; normotensive rats, 0.62 ± 0.10 vs 0.33 ± 0.08 msec/mm Hg; n = 5, p < 0.01).
In SHR, i.v. administration of AMN (1 mg/kg), a muscarinic antagonist that does not readily cross the blood-brain barrier, suppressed the i.v. phenylephrine-induced bradycardia. By contrast, i.v. administration of the /3-adrenergic blocker propranolol (1 mg/kg) did not change the phenylephrineinduced bradycardia. Propranolol (1 mg/kg i.v.) did not change basal BRS and its time-dependent increase (from 0.17 ± 0.05 to 0.33 ± 0.08 msec/mm Hg) as compared with values in control conditions.
Injections of PN 200-110 or BAY k 8644 into the lateral cerebral ventricle 45 minutes after the onset of anesthesia induced a long-lasting (>30 minutes) dose-dependent decrease and increase in blood pressure, respectively, with threshold doses of 2 and 10 /ig/kg. The maximum changes in MAP after i.c.v. administration of PN 200-110 (0.2, 0.6, 2, and 6 /ig/kg) were, respectively, +6 ± 3 {n = 5, NS), -7 ± 4 (* = 7, NS), -2 8 ± 6 (n = 6, p< 0.05), and -5 6 ± 8 mm Hg (n = 5, p < 0.01). The maximum changes in MAP after i.c.v. administration of BAY k 8644 (1, 3, 10, and 30 ^g/kg) were, respectively, +2 ± 2 (n = 5, NS), +3 ± 2 (n = 5, NS), +16 ± 5 {n = 8, p < 0.05), and +25 ± 8 mm Hg (n = 5, p < 0.05). Therefore, a 0.6 jig/kg dose of PN 200-110 and a 3 /xg/kg dose of BAY k 8644 were considered subthreshold, as concerns the changes in MAP, and were used in the subsequent experiments.
In nonnotensive rats, i.c.v. injection of BAY k 8644 (3 ^ig/kg) did not change significantly the time-dependent increase in BRS observed from the 40th to the 65th minute (from 0.30 ± 0.09 to 0.64 ± 0.11 msec/mm Hg; n = 6, p < 0.05) as compared with changes seen in the control group (from 0.33 ± 0.08 to 0.62 ±0.10 msec/mm Hg; p < 0.01, n = 5). During this period, no change in MAP was significant in either group.
The time-dependent increase in BRS during the 40th to 65th minute (from 0. and the 65th minutes after anesthesia), were not significantly different after i.c.v. injection of drugs or solvent, as compared with values before i.c.v. injection, in the three groups ( Table 2 ). The pressor effect of i.v. injected phenylephrine (2 /ig) was unchanged after i.c.v. administration of PN 200-110 (0.6 Mg/kg; before PN 200-110 the change was +78 ± 3 mm Hg; after PN 200-110 the change was +84 ± 3 mm Hg) or BAY k 8644 (3 /xg/kg; before BAY k 8644 the change was + 66 ± 3 mm Hg; after BAY k 8644 the change was +68 ± 3 mm Hg).
In Experiment 2 ( Table 1 ). MAP and HR, recorded immediately before each of the two i.v. phenylephrine injections (i.e., at the 40th and the 65th minutes after onset of anesthesia), were not significantly different after i.c.v. injection, as compared with values before i.c.v. injection, in the three groups (see Table 2 ).
In However, i.c.v. pretreatment with AMN (80 /*g/kg) antagonized the inhibitory effect of BAY k 8644 on the time-dependent increase in BRS (without AMN: from 0.11 ± 0.04 to 0.13 ± 0.03 msec/mm Hg; n = 6; with AMN: from 0.14 ± 0.04 to 0.42 ± 0.10 msec/ mm Hg; n = 7, p < 0.05). The difference between the BAY k 8644-induced change in BRS and the AMN plus BAY-induced change in BRS was significant (p < 0.05, by ANOVA). Basal values of MAP, HR, and BRS were not significantly different among the three groups (see Table 1 ). MAP and HR, recorded immediately before each of the two phenylephrine injections, were not significantly different after i.c.v. injection, as compared with values before i.c.v. injection, in the three groups (see Table 2 ). Discussion Our results indicate that a calcium channel agonist and a calcium channel antagonist may modulate the baroreceptor reflex response to phenylephrine in pentobarbital-anesthetized SHR. BRS was evaluated from the slope of the relationship between systolic arterial pressure and heart period. 23 In the present study, we focused on the changes in the time course of BRS in response to i.c.v. administration of dihydropyridines.
In anesthetized rats, arterial blood pressure variability was obviously reduced as compared with that in conscious rats. However, the inhibitory effects of pentobarbital anesthesia on BRS had to be taken into account in the interpretation of the results. The time-dependent increase in BRS was likely due to the time-dependent decrease in the inhibitory effect of anesthesia. Forty minutes after pentobarbital injection, BRS was 0.33 ± 0.08 msec/ mm Hg in normotensive rats and averaged 0.11 ± 0.01 msec/mm Hg in SHR. Sixty-five minutes after the onset of anesthesia, BRS was 0.62 ± 0.10 and 0.39 ± 0.08 msec/mm Hg in normotensive rats and in SHR, respectively. These values are close to those reported by others 24 -27 -M in conscious animals. The difference in BRS between the 65th and the 40th minutes is consistent with the twofold to threefold decrease in BRS caused by pentobarbital anesthesia in rats. 24 -" In SHR, BAY k 8644, administered i.c.v. at the 45th minute after onset of anesthesia, suppressed the time-dependent increase in BRS, since BRS determined at the 65th minute was not significantly different from BRS determined at the 40th minute. Although one may speculate on the mode of action, there is no way to identify the location of any observed effect after i.c.v. injection. The calcium channel agonist and antagonist are likely to act at almost every synapse and on every neuron in the central nervous system. The overall effect will depend on the specific cell activities during the experimental procedures and on the voltage dependence characteristic of the dihydropyridine being used. However, the purpose of this work was limited to the demonstration that calcium channel agonists and antagonists can modulate the central nervous component of the baroreceptor. reflex control of HR. Since dihydropyridine derivatives may easily pass the bloodbrain barrier after peripheral administration, a central effect of these drugs on the baroreceptor reflex control of HR is important to consider in their overall effect on blood pressure and HR.
With the rats under pentobarbital anesthesia, the phenylephrine-induced bradycardia was mainly due to an increase in vagal tone, since i.v. AMN, a muscarinic receptor antagonist that does not readily cross the blood-brain barrier, suppressed the i.v. phenylephrine-induced bradycardia. In addition, i.v. administration of the /3-adrenergic blocker propranolol did not change basal BRS and its time-dependent increase as compared with values in control conditions. However, the smaller phenylephrine-induced bradycardia observed after i.c.v. BAY k 8644 injection, as compared with values in control conditions, may have been due to a smaller increase in vagal tone or to a tonic increase in sympathetic tone unrelated to baroreceptor reflex activation, which may have buffered the baroreceptor reflex-mediated vagal stimulation. The second hypothesis is in agreement with previous reports 14 -19 showing, in SHR, an increase in sympathetic tone leading to an increase in blood pressure in response to i.c.v. administration of BAY k 8644. Since BAY k 8644 was, in the present study, i.c.v. administered at a dose that did not change blood pressure, we have to assume that this dosage was high enough to modulate the central integration of the baroreceptor reflex and low enough to induce no change in basal blood pressure.
Central cholinergic stimulation in several species, including rat, generally evoked a hypertensive response mediated by a central increase in sympathetic tone. 31 Brisac et al. 14 have reported that the pressor effect of i.c.v. administration of BAY k 8644 in SHR involved an increased muscarinic cholinergic activity. In the present study, i.c.v. administered AMN did not change the timedependent increase in BRS. However, when AMN was i.c.v. injected before BAY k 8644, it antagonized the inhibitory effect of BAY k 8644 on the time-dependent increase in BRS. These results suggest that BAY k 8644 and acetylcholine may have been acting on the same pathway. In addition, the inhibitory effect of BAY k 8644 on the timedependent increase in BRS may have been mediated by a central release of acetylcholine, the cholinergic-mediated increase in sympathetic tone buffering the baroreceptor reflex-mediated vagal stimulation and decreasing BRS.
In normotensive rats, i.c.v. BAY k 8644 administration did not change the time-dependent increase in BRS. As previously shown, 14 -19 the cardiovascular effects of BAY k 8644 and calcium channel inhibitors were more marked in SHR than in normotensive rats. Ishii et al. 32 reported a 57% increase in the maximum number of binding sites for [ 3 H]nitrendipine (a dihydropyridine molecule) in brain membranes of SHR as compared with those in normotensive Wistar-Kyoto rats. The increased number of dihydropyridine binding sites in SHR was not secondary to the high blood pressure but could be a primary abnormality in SHR. 32 Whether this increase in the maximum number of binding sites reflects an increase in functional calcium channels and explains the increased responsiveness of SHR to the centrally administered calcium channel modulators VOL 12, No 3, SEPTEMBER 1988 remains to be determined. Brisac et al. 14 showed that BAY k 8644 did not change the K + -evoked release of acetylcholine in hippocampal slices from normotensive rats, while BAY k 8644 increased it in SHR, and they suggested that the increased cholinergic activity in SHR could be related, at least in part, to an increased number of dihydropyridine binding sites. Under these conditions, the stimulation of these sites by a specific and still unknown neuromediator could lead to an enhanced release of acetylcholine and an increase in sympathetic tone and thus could participate in the genesis or the maintenance (or both) of decreased BRS in SHR. Further studies are required to assess the relative role of the cholinergic pathway involved in the effects of BAY k 8644 on the BRS as compared with pathways involving other neurotransmitters.
